WASHINGTON, Jan 22 (Reuters) - Molecular Insight Pharmaceuticals Inc. on Monday set its planned initial public offering at 5 million shares for an estimated price of $14 to $16 each.
WASHINGTON, Jan 22 (Reuters) - Molecular Insight Pharmaceuticals Inc. on Monday set its planned initial public offering at 5 million shares for an estimated price of $14 to $16 each.